Gurdov Shatlyk¹* and Chovdyrov Orazmyrat¹ and Chachayev Begench²

¹Hospital with a Scientific and Clinical Center of Cardiology, Ashgabat, Turkmenistan
²International Cardiology Center, Ashgabat, Turkmenistan

*Corresponding Author: Gurdov Shatlyk, Hospital with a Scientific and Clinical Center of Cardiology, Ashgabat, Turkmenistan.

Received: December 01, 2023; Published: January 20, 2024

Abstract

Introduction: Miocardial effects during and after ischemia were studied using cryoprotective crystalloid cardioplegic (CCC) solution colled below 0o C to -5o C during open heart surgery.

Objective: Comparison of structural and functional parameters of the heart in cardiopulmonary bypass patients undergoing cardioplegia.

Methods: Protected by patent No. 819 dated 02.2020, it contains: pH 7,74; pCO2 is low; pO2 163,1 mmHg; BE +4,9 mmol/l; K+ 10,0 mmol/l; Ca++ 0 mmol/l; less Na+ mmol/l; Cl - 110 mmol/l; Glucose 273 mmol/l; Lactate 0 mmol/l. The composition of the solution includes: Glucose 5% 450,0 ml; 10 ml of potassium chloride 4%; 31 ml of sodium bicarbonate 4%; cryoprotectants 9 ml. The tests were conducted on pigs between 2016 and 2018. Since the beginning of 2020, it has been used in our hospital during cardiac surgery in patients with congenital heart defects, later acquired heart failure and ischemic heart disease.

Results: The dose of the solution is 7,5-10,0 ml/kg of the patient. The effect of the introduction of this solution into the coronary arteries occurs after 35-45 seconds through bradycardia, after which asystole continues for more than 90 minutes. If it is necessary to extend the myocardial protection time to 120 minutes, half the calculated dose of this solution should be administered. Restoration of the heart rhythm after removing the clamp from the aorta occurs after 3-4 minutes on its own through bradycardia (nodal rhythm) or large-wave fibrillation without cardioversion and cardiotonics. The solution acts due to a non-penetrating cryoprotectant of general action and membrane-stabilizing, enzyme-differentiating penetrating cryoprotectors with conformational flexibility and refrigerant capacity. Histological studies of the myocardium after 60 and 120 minutes of cardioplegia revealed edema in 25% and 45% of cardiomycs. After 15-30 minutes of myocardial reperfusion, cardiomyocyte edema disappears. Cardiomarkers: Creatine kinase - MB - initially less than 1.0 ng/ml; after cardioplegia 1,0 ng/ml. Myoglobin - initially 56,9 ng/ml; after 51,2 ng/ml. Troponin - initially 0,03 μg/l; after 0,03 μg/l. All myocardial structures during heart surgery remain intact.

Conclusion: With a 500 ml volume of a new CCC solution, the heart can be protected from ischemia continuously, safely and the best during surgery.

Keywords: Heart Surgery; Cardioplegic Solution; To Cool; Myocardial Effects; Reliable; Seamless; Patent

References

1. Alexi-Meskishvili V and Böttcher W. “Suturing of penetrating wounds to the heart in the nineteenth century: The beginnings of heart surgery”. The Annals of Thoracic Surgery 92 (2011): 1926-1931.
2. Shumacker HB Jr. “The Evolution of Cardiac Surgery”. Indiana University Press: Bloomington, Indiana, (1992).
3. Westaby S and Bosher C. “Landmarks in Cardiac Surgery”. Isis Medical Media Ltd.: Oxford, UK, (1997).
4. Ellis H. “The early days of surgery for cardiac injuries”. Journal of Perioperative Practice 7 (2017): 268.
5. Cohn LH. “The first successful surgical treatment of mitral stenosis: The 70th anniversary of Elliot Cutler’s mitral commissurotomy”. The Annals of Thoracic Surgery 56 (1993): 1187-1190.
6. Cooley DA and Frazier OH. “The past 50 years of cardiovascular surgery”. Circulation 102 (2000): IV87-IV93.
7. Baust JG., et al. “Biopreservation - reducing the negative effects of conservation at the molecular level”. Problems Cryobiology 18 (2008): 2-163.
8. Sealy WC. “Hypothermia: Its possible role in cardiac surgery”. The Annals of Thoracic Surgery 47 (1989): 788-791.
9. Lewis FJ., et al. “Closure of atrial septal defects with the aid of hypothermia; experimental accomplishments and the report of one successful case”. Surgery 33 (1953): 52-59.
10. Gibbon JH Jr. “The development of the heart-lung apparatus”. The American Journal of Surgery 135 (1978): 608-619.
11. Kirklin JW., et al. “Intracardiac surgery with the aid of a mechanical pump-oxygenator system (gibbon type): Report of eight cases”. Proc. Staff Meet. Mayo Clin. 30 (1955): 201-206.
12. Nardid OA. “Study of the effect of low-molecular cryoprotectants on the mitochondrial respiratory chain using the EPR spin probe method”. Problems Cryobiology12 (2009): 172-185.
13. Brewer DL., et al. “Myocardial infarction as a complication of coronary bypass surgery”. Circulation 47 (1973): 58.
14. Hultgren HN., et al. “Ischemic myocardial injury during cardiopulmonary bypass surgery”. American Heart Journal 85 (1973): 167.
15. Osutsky AI., et al. “On the mechanism of protection of cryopreserved biological objects using multicomponent cryoprotective solutions”. Problems of cryobiology 18 (2008): 2 - 231.
16. Lam CR., et al. “Clinical experiences with Induced cardiac arrest during intracardiac surgical procedures”. Annals of Surgery 146 (1957): 439-449.
17. Schaff HV., et al. “Effect of K+ cardioplegia on myocardial ischemia and post arrest ventricular function”. Circulation 58 (1978): 240-249.
18. Allen P., et al. “Use of induced cardiac arrest in open heart surgery; results in seventy patients”. Minnesota Medicine 40 (1957): 672-676.
19. Nunn DD., et al. “A comparative study of aortic occlusion alone and of K+ citrate arrest during cardio pulmonary bypass”. Surgery 45 (1959): 848-851.
20. Wasserman F., et al. “Comparative effect of 5 per cent K+ chloride and 30 percent K+ citrate in resuscitation from ventricular fibrillation following acute myocardial infarction; an experimental study”. The Journal of Thoracic and Cardiovascular Surgery 38 (1959): 30-39.
21. Willman VL., et al. “Depression of ventricular function following elective cardiac arrest with K+ citrate”. Surgery 46 (1959): 792-796.
22. Bjork VO and Fors B. “Induced cardiac arrest”. The Journal of Thoracic and Cardiovascular Surgery 41 (1961): 387-394.
23. Hufnagel CA., et al. “Profound cardiac hypothermia”. Annals of Surgery 153 (1961): 790.
24. Griepp RB., et al. “Profound local hypothermia for myocardial protection during open-heart surgery”. The Journal of Thoracic and Cardiovascular Surgery 66 (1973): 731.
25. Shumway NE and Lower RR. “Topical cardiac hypothermia for extended periods of anoxic arrest”. Surgical Forum 10 (1960): 563.
26. Shumway NE., et al. “Selective hypothermia of the heart in anoxic cardiac arrest”. Surgery, Gynecology and Obstetrics 109 (1959): 750.
27. Cooley DA., et al. “Ischemic myocardial contracture (“stone heart”). A complication of cardiac surgery”. Israel Medical Association Journal 11 (1975): 203-210.
28. Bretschneider HJ. “Survival time and recuperative time of the heart in normothermia and hypothermia”. Dtsch. Ges. Kreislaufforsch 30 (1964): 11-34.
29. Bretschneider HJ., et al. “Myocardial resistance and tolerance to ischemia: Physiological and biochemical basis”. Journal of Cardiovascular Surgery 16 (1975): 241-260.
30. Preusse CJ. “Cardioplegia with an intracellular formulation”. In Ischemia-Reperfusion in Cardiac Surgery; Piper, H.M., Preusse, C.J., Eds.; Springer: Dordrecht, Netherlands (1993).
31. Braimbridge MV., et al. “Cold cardioplegia or continuous coronary perfusion? Report on preliminary clinical experience as assessed cytochemically”. The Journal of Thoracic and Cardiovascular Surgery 74 (1977): 900-906.
32. Gonzales AC., et al. “Acute right ventricular faillure is caused by inadequate right ventricular hypothermia”. The Journal of Thoracic and Cardiovascular Surgery 89 (1985): 386-399.
33. Hearse DJ., et al. “Protection of the Ischemic Myocardium: Cardioplegia”. Raven Press: New York, NY, USA (2012).

Citation

Citation: Gurdov Shatlyk., et al. “Innovative CCC Solution for Open Heart Surgery".Acta Scientific Clinical Case Reports 5.2 (2024): 24-26.

Copyright

Copyright: © 2024 Gurdov Shatlyk., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.